--- title: UKCA Marking vs. CE Marking: What EU Startups Need to Know in 2026 description: Side-by-side comparison of UKCA marking and CE marking for medical devices. Key differences, practical implications, and dual-marking strategies for EU MedTech startups. authors: Tibor Zechmeister, Felix Lenhard category: MDR Fundamentals & Regulatory Strategy primary_keyword: canonical_url: https://zechmeister-solutions.com/en/blog/ukca-marking-vs-ce-marking-eu-startups-2026 source: zechmeister-solutions.com license: All rights reserved. Content may be cited with attribution and a link to the canonical URL. --- # UKCA Marking vs. CE Marking: What EU Startups Need to Know in 2026 *By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.* Two markets. Two marks. Two regulatory frameworks. Two conformity assessment bodies. For an EU MedTech startup that wants to sell in both the EU and the UK, understanding the differences between CE marking (under MDR) and UKCA marking (under UK regulations) is essential for planning your regulatory strategy and budget. This post provides a direct, side-by-side comparison. ## The Big Picture | Aspect | CE Marking (EU) | UKCA Marking (UK) | |--------|----------------|-------------------| | Regulation | MDR (EU) 2017/745 | UK Medical Devices Regulations 2002 (as amended) | | Territory | EU/EEA (27 Member States + Iceland, Liechtenstein, Norway) | Great Britain (England, Scotland, Wales) | | Competent Authority | National competent authorities of each Member State | MHRA | | Conformity Assessment Body | EU Notified Bodies | UK Approved Bodies | | Database | EUDAMED | MHRA registration system | | Representative Requirement | EU Authorized Representative (for non-EU manufacturers) | UK Responsible Person (for non-UK manufacturers) | | Classification | MDR Annex VIII (22 rules) | UK classification rules (derived from MDD/AIMDD) | ## Detailed Comparison ### Regulatory Framework **CE Marking:** Based on MDR (EU) 2017/745, which represents a significant overhaul of the previous Medical Device Directives. MDR introduces more rigorous requirements across the board. Stricter clinical evidence, mandatory post-market surveillance, UDI, EUDAMED, Person Responsible for Regulatory Compliance, and more. **UKCA Marking:** Based on the UK Medical Devices Regulations 2002, which were originally derived from the EU Medical Device Directives (MDD/AIMDD). The UK has announced plans to modernize its framework, but as of 2026, the underlying regulations still reflect the old directive structure rather than the MDR overhaul. **Implication for startups:** If you have built your regulatory compliance for MDR (which is the more demanding framework), transitioning to UK compliance may be relatively straightforward. Your documentation exceeds the current UK requirements in many areas. However, you cannot simply assume compliance; the UK requirements must be separately verified. ### Classification **CE Marking:** MDR Annex VIII with 22 classification rules. Notable changes from MDD include stricter classification for software (Rule 11), nanomaterials, and substances. **UKCA Marking:** The UK classification rules are currently based on the MDD classification system. This means some devices may be classified differently in the UK than under MDR. **Implication for startups:** A software medical device classified as Class IIa under MDR Rule 11 may have a different classification under UK rules (potentially lower). Verify the classification under both systems. It affects the conformity assessment route in each jurisdiction. ### Conformity Assessment Bodies **CE Marking:** EU Notified Bodies designated by Member State authorities and listed in the NANDO database. Competence assessed against MDR requirements. **UKCA Marking:** UK Approved Bodies designated by MHRA. The UK has been building its Approved Body infrastructure post-Brexit. **Implication for startups:** Your EU Notified Body cannot issue a UKCA certificate, and a UK Approved Body cannot issue a CE marking certificate. If you need both marks, you need relationships with assessment bodies in both jurisdictions. Some organizations operate as both EU Notified Bodies and UK Approved Bodies (often through affiliated entities in each jurisdiction), which can simplify coordination. ### Clinical Evidence **CE Marking:** MDR Article 61 with strict clinical evidence requirements, tightened equivalence provisions, and mandatory post-market clinical follow-up. **UKCA Marking:** Clinical evidence requirements under the current UK framework are based on the MDD standard. Still rigorous but generally less demanding than MDR, particularly regarding equivalence and post-market clinical follow-up. **Implication for startups:** Clinical evidence generated for MDR compliance will generally exceed UK requirements. Your CER may need to be adapted (different regulatory references, different format expectations) but the underlying data should be transferable. ### Post-Market Surveillance **CE Marking:** MDR establishes comprehensive PMS requirements including PMS plan, PMS report (Class I) or PSUR (Class IIa and above), PMCF, and integration with vigilance. **UKCA Marking:** UK PMS requirements exist but are currently based on the MDD framework. The UK has signaled intent to modernize PMS requirements as part of its regulatory reform. **Implication for startups:** Your MDR PMS system will likely meet or exceed UK requirements. Ensure that your PMS system includes UK-specific data collection (UK complaints, UK incident reports) and UK-specific reporting (to MHRA). ### Device Registration **CE Marking:** Registration in EUDAMED (to the extent modules are operational). UDI implementation required. **UKCA Marking:** Registration with MHRA through their device registration system. The UK has its own UDI requirements. **Implication for startups:** Separate registrations in separate systems. Budget time and administrative effort for both. Ensure your labeling accommodates both UDI systems if you sell in both markets. ### Labeling **CE Marking:** MDR Annex I Chapter III labeling requirements, including the CE mark with NB four-digit number (where applicable), and language requirements for each Member State. **UKCA Marking:** UK labeling requirements including the UKCA mark and UK Responsible Person's contact information. Instructions for use must be in English. **Implication for startups:** You may need dual-marked labels (CE + UKCA) or separate label variants for EU and UK markets. Plan your labeling production to accommodate both. The physical space on small devices or packaging can be a practical constraint. ### Vigilance **CE Marking:** Serious incident reporting to the competent authority of the Member State where the incident occurred, with reporting timelines defined in MDR Articles 87-92. **UKCA Marking:** Adverse incident reporting to MHRA per UK regulations. **Implication for startups:** You need vigilance systems that cover both jurisdictions. An incident in the UK must be reported to MHRA; an incident in the EU must be reported to the relevant Member State authority. For a company selling in both markets, the vigilance process must route reports to the correct authority based on where the incident occurred. ## Dual-Marking Strategy For startups that need both marks, here are strategic approaches: ### Strategy 1: Sequential (EU First, Then UK) Get your CE mark first. Use the EU technical documentation as the foundation for the UK submission. Engage a UK Approved Body once your EU documentation is mature. **Advantages:** Focused effort. Lower risk of divided attention. The more demanding EU process creates a strong foundation for the UK. **Disadvantages:** Delayed UK market entry. ### Strategy 2: Parallel (Both Simultaneously) Engage both an EU Notified Body and a UK Approved Body from the start. Develop documentation that serves both jurisdictions. **Advantages:** Faster access to both markets. Potentially lower total cost if documentation development is coordinated. **Disadvantages:** Higher complexity. Requires more regulatory resource bandwidth. Risk of divided focus. ### Strategy 3: Coordinated Bodies Choose a Notified Body and Approved Body that are affiliated (same parent organization or formal partnership). This can streamline documentation review and reduce duplication. **Advantages:** Coordinated reviews. Potentially shared documentation. Single point of contact for questions. **Disadvantages:** May limit your choice of assessment bodies. Not all NB/AB combinations offer this coordination. ## Cost of Dual Compliance The incremental cost of adding UKCA marking to an existing CE marking program: | Category | Incremental Cost Estimate | |----------|--------------------------| | UK Approved Body fees | EUR 15,000 - 80,000 (comparable to EU NB fees for similar class) | | UK Responsible Person | EUR 3,000 - 15,000/year | | MHRA registration | EUR 1,000 - 5,000 | | Documentation adaptation | EUR 5,000 - 20,000 | | Labeling changes | EUR 2,000 - 10,000 | | Additional regulatory support | EUR 5,000 - 15,000 | | **Total incremental** | **EUR 30,000 - 145,000 initial + annual maintenance** | For a startup with a single device, this is a significant but manageable addition to the regulatory budget if the UK market justifies the investment. ## When NOT to Pursue UKCA For some startups, UKCA marking is not worth pursuing in the near term: - **If UK market revenue projections are small** relative to the regulatory investment - **If your device class is high** (Class IIb or III) and the dual assessment burden is prohibitive - **If your team lacks bandwidth** to manage two parallel regulatory relationships - **If the UK regulatory framework is still in flux** and you prefer to wait for clarity There is no obligation to sell in the UK. Many EU startups succeed with EU market access alone, and the UK can be added later when the company has more resources and the regulatory framework has stabilized. Tibor's practical view: "For a startup with limited resources, my recommendation is almost always: EU first, UK later. The EU market is seven times larger in population. The regulatory requirements under MDR are more demanding, so the work you do for CE marking creates a strong foundation for UK compliance whenever you are ready. Trying to do both from day one spreads your resources too thin." ## Looking Forward The UK regulatory landscape for medical devices is evolving. The MHRA has signaled a commitment to a modern, innovation-friendly regulatory framework. Some elements may align with MDR, others may diverge. The final shape is not yet clear. For EU startups, the best preparation is: 1. Build robust MDR compliance (this is your primary market and your strongest regulatory foundation) 2. Stay informed about UK regulatory developments (subscribe to MHRA updates) 3. Budget for UK market access when the time is right 4. Choose flexible labeling and documentation approaches that can accommodate both jurisdictions The separation of EU and UK medical device regulation is permanent. The specific requirements will stabilize over time, and the dual-market pathway will become routine. Until then, plan pragmatically, invest proportionally, and keep your primary focus on the larger EU market. ## The Bottom Line UKCA and CE marking serve the same fundamental purpose. Demonstrating that a medical device meets safety and performance requirements. But they operate under different regulations, different assessment bodies, and different authorities. For EU startups, CE marking under MDR is the priority. UKCA marking is an additional investment justified by UK market opportunity. The frameworks are similar enough that one set of technical work largely supports both. But different enough that separate conformity assessments, registrations, and ongoing compliance activities are required. Plan accordingly, budget accordingly, and time your UK market entry based on your company's resources and market priorities. --- *This post is part of the [MDR Fundamentals & Regulatory Strategy](https://zechmeister-solutions.com/en/blog/category/mdr-fundamentals) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*